NEW YORK – Roche subsidiary Foundation Medicine announced on Monday that its FoundationOne CDx test received approval from the US Food and Drug Administration for use as a companion diagnostic for Janssen Biotech's Akeega (niraparib and abiraterone acetate).
The drug, administered in a dual-action tablet, was approved by the FDA to treat adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, Foundation Medicine said in a statement. FoundationOne CDx is a next-generation sequencing-based test that uses a tissue sample to analyze 324 cancer-related genes to detect genomic alterations in a patient's tumor and has more than 30 companion diagnostic indications.
"With such a rapidly evolving therapeutic landscape in prostate cancer, high-quality companion diagnostics are important tools to support oncologists in the development of personalized treatment plans for each unique patient," Mia Levy, Foundation Medicine's chief medical officer, said in a statement, adding that FoundationOne CDx "specifically will help enable broader access to an important new therapy option" in BRCA-mutated metastatic castration-resistant prostate cancer.